TY - JOUR
T1 - Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy
AU - Chaban, Artem
AU - Waschulzik, Birgit
AU - Bernhardt, Denise
AU - Delbridge, Claire
AU - Schmidt-Graf, Friederike
AU - Wagner, Arthur
AU - Wiestler, Benedikt
AU - Weber, Wolfgang
AU - Yakushev, Igor
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/5
Y1 - 2024/5
N2 - Purpose: To summarize evidence on the comparative value of amino acid (AA) PET and conventional MRI for prediction of overall survival (OS) in patients with recurrent high grade glioma (rHGG) under bevacizumab therapy. Methods: Medical databases were screened for studies with individual data on OS, follow-up MRI, and PET findings in the same patient. MRI images were assessed according to the RANO criteria. A receiver operating characteristic curve analysis was used to predict OS at 9 months. Results: Five studies with a total of 72 patients were included. Median OS was significantly lower in the PET-positive than in the PET-negative group. PET findings predicted OS with a pooled sensitivity and specificity of 76% and 71%, respectively. Corresponding values for MRI were 32% and 82%. Area under the curve and sensitivity were significantly higher for PET than for MRI. Conclusion: For monitoring of patients with rHGG under bevacizumab therapy, AA-PET should be preferred over RANO MRI.
AB - Purpose: To summarize evidence on the comparative value of amino acid (AA) PET and conventional MRI for prediction of overall survival (OS) in patients with recurrent high grade glioma (rHGG) under bevacizumab therapy. Methods: Medical databases were screened for studies with individual data on OS, follow-up MRI, and PET findings in the same patient. MRI images were assessed according to the RANO criteria. A receiver operating characteristic curve analysis was used to predict OS at 9 months. Results: Five studies with a total of 72 patients were included. Median OS was significantly lower in the PET-positive than in the PET-negative group. PET findings predicted OS with a pooled sensitivity and specificity of 76% and 71%, respectively. Corresponding values for MRI were 32% and 82%. Area under the curve and sensitivity were significantly higher for PET than for MRI. Conclusion: For monitoring of patients with rHGG under bevacizumab therapy, AA-PET should be preferred over RANO MRI.
KW - Avastin
KW - Glioblastoma
KW - Magnetic resonance imaging
KW - Positron emission tomography
KW - Pseudoresponse
KW - Therapy monitoring
UR - https://www.scopus.com/pages/publications/85182459398
U2 - 10.1007/s00259-024-06601-4
DO - 10.1007/s00259-024-06601-4
M3 - Article
C2 - 38228970
AN - SCOPUS:85182459398
SN - 1619-7070
VL - 51
SP - 1698
EP - 1702
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 6
ER -